Circulating Tumor DNA and Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Hepatocellular carcinoma (HCC) lacks effective biomarkers for early detection and prognosis.
• Circulating cell-free DNA (cfDNA) and its tumor-derived fraction, circulating tumor DNA (ctDNA), are emerging as promising blood-based biomarkers.
• Previous research indicated the diagnostic and prognostic value of cfDNA quantification in HCC.

Purpose of the Study:

• To review current ctDNA detection technologies for HCC.
• To evaluate the diagnostic and prognostic performance of ctDNA in HCC.
• To identify future research directions for ctDNA in HCC.

Main Methods:

• Review of existing literature on ctDNA detection technologies.
• Analysis of studies utilizing next-generation sequencing for ctDNA mutational and methylation profiling.
• Discussion of diagnostic and prognostic performance data.

Main Results:

• Hotspot mutation panels and methylation panels derived from ctDNA show promising performance in HCC.
• Quantitative cfDNA measurements have demonstrated diagnostic and prognostic utility.
• No ctDNA tests have been validated in longitudinal cohorts for preclinical HCC detection.

Conclusions:

• ctDNA analysis, including mutation and methylation profiling, holds significant potential for HCC biomarker development.
• Further validation in longitudinal cohorts is crucial for preclinical detection and clinical application of ctDNA-based tests.
• Continued research into ctDNA technologies is essential for advancing HCC diagnostics and prognostics.